Skip Navigation LinksHome > September 2012 - Volume 18 - Issue 6 > Etanercept Therapy for Psoriatic Arthritis in the Presence o...
JCR: Journal of Clinical Rheumatology:
doi: 10.1097/RHU.0b013e3182685515
Case Reports

Etanercept Therapy for Psoriatic Arthritis in the Presence of Recurrent Non–Hodgkin Lymphoma

Pai, Sneha MD*; Rosenstein, Elliot D. MD, FACP, FACR; Kramer, Neil MD, FACP, FACR

Collapse Box


Abstract: Tumor necrosis factor inhibitors (TNFi) have established efficacy in psoriasis and psoriatic arthritis; however, there are concerns regarding the risk of lymphoma with their use. Although current data suggest that this risk is not increased with TNFi treatment, there are no data on the risk of recurrence of previously treated lymphoma under TNFi therapy. Herein, we describe a 46-year-old man with recurrent non–Hodgkin lymphoma whose refractory psoriatic arthritis was effectively treated for 5.5 years with the TNFi etanercept, initiated just 7 months after achieving lymphoma remission, without recurrence of non–Hodgkin lymphoma. However, he subsequently died 6.5 years later of pancreatic adenocarcinoma.

© 2012 Lippincott Williams & Wilkins, Inc.

Follow Us!


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.